Study to Assess Safety, Tolerability and Pharmacokinetics after Single Doses of AZD2516 to Healthy Volunteers

Study identifier:D2080C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers after Oral Single Ascending Doses

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2516, Placebo

Sex

All

Actual Enrollment

72

Study type

Interventional

Age

20 Years - 80 Years

Date

Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Nov 2008
Study Completion Date: 01 Dec 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria